Daiichi Sankyo Co.

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Daiichi Sankyo Co. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Daiichi Sankyo Co.: 8 sponsored US clinical trials, none currently recruiting.

Daiichi Sankyo Co. sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Malignant, with 1 trials.

Upper-quartile sponsor footprint

Daiichi Sankyo Co. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

NCT03401385
ACTIVE NOT RECRUITING Phase 1

DS-3201b in Participants With Lymphomas

NCT02732275
TERMINATED Phase 1

A Study of DS-1471a In Subjects With Advanced Solid Tumors

NCT06074705
COMPLETED Early Phase 1

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

NCT04459585
COMPLETED Phase 1

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

NCT04459598
COMPLETED Phase 2

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

NCT03384940
COMPLETED Phase 1

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

NCT02980341
COMPLETED Phase 1

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

NCT02564900

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1

Therapeutic Areas

Lymphoma, Malignant 1
Non-Hodgkin Lymphoma 1
Hormone Receptor-Positive Breast Cancer 1
Triple Negative Breast Cancer 1
Advanced Solid Tumors 1
Non-Small Cell Lung Cancer 1

How the Daiichi Sankyo Co. early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Lymphoma, Malignant (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Daiichi Sankyo Co.: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Daiichi Sankyo Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Daiichi Sankyo Co.AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Daiichi Sankyo Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Daiichi Sankyo Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Daiichi Sankyo Co. page

8 registered trials is a research-attention snapshot, not an endorsement of Daiichi Sankyo Co. or any single study.

  • None of Daiichi Sankyo Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Lymphoma, Malignant is the condition Daiichi Sankyo Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Malignant trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Daiichi Sankyo Co. pipeline card: 8 registered trials from official public datasets.Report a data error.